文献速递免疫规划卫生政策与健康促进

2024-25呼吸道病毒季节末美国60-74岁高风险及≥75岁成人RSV疫苗接种覆盖率

RSV vaccination uptake by the end of the 2024-25 respiratory virus season among adults aged 60-74 years at increased risk of severe RSV and adults aged ≥75 years.
PubMed 文献 · Vaccine · 2026-03-11

研究基于2024年9月至2025年4月国家免疫调查-成人COVID模块数据,采用Kaplan-Meier法评估美国60-74岁RSV重症高风险成人及≥75岁成人RSV疫苗接种覆盖率。结果显示两类人群接种率分别为38.3%和41.5%,且各州/领地差异显著。收入、教育、无残疾及医生推荐与接种率升高独立相关。

要点

  • 2024-25季节末60-74岁高风险成人RSV接种率为38.3%,≥75岁成人为41.5%。
  • 接种率在各州/领地间差异大,60-74岁高风险人群从10.8%至61.2%不等。
  • 医生推荐、较高收入与教育水平及无残疾与接种率升高独立相关。

核心结论

  • 2024-25季节末美国60-74岁RSV重症高风险成人及≥75岁成人RSV疫苗接种覆盖率仍较低。
  • 各州/领地间接种覆盖率存在广泛差异,且不同人口学特征人群接种率不同。

研究设计与样本

  • 分析2024年9月至2025年4月收集的国家免疫调查-成人COVID模块数据。
  • 采用Kaplan-Meier生存分析评估全国及州级RSV疫苗接种覆盖率。
  • 使用多变量逻辑回归和预测边际分析评估与接种相关的因素。

主要发现

  • 60-74岁高风险成人接种率为38.3%,其中56.2%在2024-25季节开始前已接种。
  • ≥75岁成人接种率为41.5%,其中55.4%在2024-25季节开始前已接种。
  • 60-74岁高风险成人接种率范围从维尔京群岛的10.8%到密歇根州的61.2%。
  • ≥75岁成人接种率范围从维尔京群岛的7.2%到科罗拉多州的57.6%。
  • 家庭收入高于贫困线、大学本科及以上教育、无残疾及获得医生推荐与两类人群接种率升高独立相关。

关键数值与推荐

  • 2024年美国ACIP推荐60-74岁RSV重症高风险成人及所有≥75岁成人接种RSV疫苗。

临床怎么用

  • 医疗服务提供者应教育并鼓励符合条件的成人接种RSV疫苗。
  • 可针对低收入、低教育水平、有残疾及未获医生推荐的人群加强接种促进。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Older adults are more likely to develop severe respiratory syncytial virus (RSV) disease and need hospitalization. In 2024, RSV vaccination was recommended in the United States by ACIP. for adults aged 60-74 years at increased risk of severe RSV and all adults aged ≥75 years. METHODS: Data from the National Immunization Survey-Adult COVID Module collected during September 2024-April 2025 were analyzed to assess RSV vaccination coverage at national and state level using the Kaplan-Meier survival analysis procedure. Multivariable logistic regression analysis and predictive marginals were conducted to assess factors associated with RSV vaccination. RESULTS: RSV vaccination coverage by the end of the 2024-25 season among adults aged 60-74 years at increased risk of severe RSV and adults aged ≥75 years was 38.3% and 41.5%, respectively, and of those who had ever received RSV vaccination, 56.2% and 55.4%, respectively, reported receiving it before start of the 2024-25 season. Coverage ranged from 10.8% in Virgin Islands to 61.2% in Michigan among adults aged 60-74 years at increased risk, and 7.2% in Virgin Islands to 57.6% in Colorado among adults aged ≥75 years. Characteristics independently associated with increased RSV vaccination among both adults aged 60-74 years at increased risk of severe RSV and adults aged ≥75 years included household income above the poverty level, having college graduate or higher education, not having a disability, and receiving provider recommendation for RSV vaccination. CONCLUSIONS: By the end of the 2024-25 season, RSV vaccination coverage among adults aged 60-74 years at increased risk of severe RSV and adults aged ≥75 years remains low in the United States. Wide variation in coverage across states/territories were observed. Differences by demographic and other factors were observed in vaccination uptake. Healthcare providers can educate and encourage adults to receive vaccine when they are eligible.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lu PJ, Hung MC, Srivastav A, et al. RSV vaccination uptake by the end of the 2024-25 respiratory virus season among adults aged 60-74 years at increased risk of severe RSV and adults aged ≥75 years. Vaccine. 2026. PMID: 41819637. doi:10.1016/j.vaccine.2026.128427

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。